Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

customer fills up car with gasoline
Dividend Stocks

Oil Shock, Rate Decision Ahead: 3 TSX Stocks Built for Both

These stocks can hold up better when oil shocks and rate fears make markets choppy.

Read more »

ETF stands for Exchange Traded Fund
Stocks for Beginners

3 Canadian ETFs I’d Seriously Consider Adding to My Portfolio in 2026

The idea is to dollar-cost average into your selected core long-term ETFs over time to build long-term wealth.

Read more »

Muscles Drawn On Black board
Dividend Stocks

Canadian Defensive Stocks to Buy Now for Stability

These Canadian defensive stocks are supported by fundamentally strong businesses, offering stability and growth in all market conditions.

Read more »

dividend growth for passive income
Metals and Mining Stocks

This Stellar Canadian Stock Is up 114% This Past Year, and There’s More Growth Ahead

Barrick Mining (TSX:ABX) remains a hot bet, even after its bearish dip.

Read more »

workers walk through an office building
Dividend Stocks

4 Canadian Stocks Worth Adding to Give Your TFSA a Fresh Direction

Shore up your self-directed TFSA portfolio by adding these four TSX stocks to your radar because the underlying businesses are…

Read more »

A meter measures energy use.
Dividend Stocks

2 Canadian Utility Stocks That Could Be Headed for a Strong 2026

Two Canadian utility stocks are likely to sustain their upward momentum and finish strong in 2026.

Read more »

people ride a downhill dip on a roller coaster
Stocks for Beginners

The Smartest TSX Stock to Buy With $500 Right Now

A $500 bet on Cineplex lets you ride a Canadian brand’s recovery while the stock still reflects plenty of skepticism.

Read more »

tree rings show growth patience passage of time
Dividend Stocks

2 Canadian Lumber Stocks to Watch Right Now

These lumber stocks could benefit from stable demand in construction and infrastructure.

Read more »